Novo after crucial data from competitor: Welcomes drug R&D
Investors in both Novo Nordisk and US firm Eli Lilly are highly satisfied with the results from Lilly's grand diabetes hope, tirzepatide. Novo Nordisk already has a potential new superdrug in its pipeline.
BY BENJAMIN WERNER CHRISTENSEN, FINANS, TRANSLATED BY NIELSINE NIELSEN
Things looked really great, but not to the extent that the firms have hit a home run.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
